0000316011-25-000087.txt : 20251124 0000316011-25-000087.hdr.sgml : 20251124 20251124160006 ACCESSION NUMBER: 0000316011-25-000087 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20251121 FILED AS OF DATE: 20251124 DATE AS OF CHANGE: 20251124 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LILLY ENDOWMENT INC CENTRAL INDEX KEY: 0000316011 ORGANIZATION NAME: STATE OF INCORPORATION: IN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-06351 FILM NUMBER: 251512735 BUSINESS ADDRESS: STREET 1: 2801 NORTH MERIDIAN STREET CITY: INDIANANAPOLIS STATE: IN ZIP: 46208 BUSINESS PHONE: 3179245471 MAIL ADDRESS: STREET 1: 2801 NORTH MERIDIAN ST CITY: INDIANAPOLIS STATE: IN ZIP: 46208 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ELI LILLY & Co CENTRAL INDEX KEY: 0000059478 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 350470950 STATE OF INCORPORATION: IN FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: LILLY CORPORATE CTR STREET 2: DROP CODE 1094 CITY: INDIANAPOLIS STATE: IN ZIP: 46285 BUSINESS PHONE: 3172762000 MAIL ADDRESS: STREET 1: LILLY CORPORATE CENTER STREET 2: DROP CODE 1094 CITY: INDIANAPOLIS STATE: IN ZIP: 46285 FORMER COMPANY: FORMER CONFORMED NAME: LILLY ELI & CO DATE OF NAME CHANGE: 19941024 4 1 form4-11242025_041101.xml X0508 4 2025-11-21 0000059478 ELI LILLY & Co LLY 0000316011 LILLY ENDOWMENT INC 2801 NORTH MERIDIAN STREET INDIANAPOLIS IN 46208-0068 false false true false 0 Common Stock 2025-11-21 4 S 0 9871 1050.272 D 92597433 D Common Stock 2025-11-21 4 S 0 5506 1051.484 D 92591927 D Common Stock 2025-11-21 4 S 0 2885 1052.361 D 92589042 D Common Stock 2025-11-21 4 S 0 1987 1053.458 D 92587055 D Common Stock 2025-11-21 4 S 0 1629 1054.422 D 92585426 D Common Stock 2025-11-21 4 S 0 2495 1055.452 D 92582931 D Common Stock 2025-11-21 4 S 0 1546 1056.396 D 92581385 D Common Stock 2025-11-21 4 S 0 5064 1057.584 D 92576321 D Common Stock 2025-11-21 4 S 0 9729 1058.461 D 92566592 D Common Stock 2025-11-21 4 S 0 23916 1059.658 D 92542676 D Common Stock 2025-11-21 4 S 0 7582 1060.531 D 92535094 D Common Stock 2025-11-21 4 S 0 10492 1061.559 D 92524602 D Common Stock 2025-11-21 4 S 0 9051 1062.517 D 92515551 D Common Stock 2025-11-21 4 S 0 8576 1063.572 D 92506975 D Common Stock 2025-11-21 4 S 0 3378 1064.433 D 92503597 D Common Stock 2025-11-21 4 S 0 1459 1065.569 D 92502138 D Common Stock 2025-11-21 4 S 0 160 1066.15 D 92501978 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,050.00 to $1,050.997, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), and (16) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,051.00 to $1,051.994, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,052.00 to $1,052.96, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,053.00 to $1,053.99, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,054.00 to $1,054.99, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,055.00 to $1,055.969, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,056.00 to $1,056.99, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,057.00 to $1,057.97, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,058.022 to $1,059.005, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,059.034 to $1,060.032, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,060.037 to $1,061.036, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,061.039 to $1,062.022, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,062.043 to $1,063.04, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,063.051 to $1,064.042, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,064.07 to $1,065.03, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,065.118 to $1,066.00, inclusive. /s/ Diane M. Stenson, Vice President and Treasurer, on behalf of Lilly Endowment Inc. 2025-11-24